B Mirror Report:  The Dhaka Stock Exchange (DSE) states that 29 of the 34 listed companies in the pharmaceutical and chemicals sector have released their unaudited financial reports for the October–December 2025 quarter thus far. As per data that was made public, 19 companies saw an increase in profits per share (EPS) during the quarter. Five companies, meanwhile, saw a drop in profits, while five continued to lose money.

Among the companies that reported higher EPS are ACI, ACI Formulations, Acme Laboratories, MB Pharma, Asiatic Laboratories, Beacon Pharmaceuticals, Beximco Pharmaceuticals, Ibn Sina, Indo-Bangla Pharma, Kohinoor Chemical, Marico Bangladesh, Navana Pharmaceuticals, Orion Infusion, Pharma Aids, Renata, Salvo Organic Industries, Silco Pharma, Square Pharmaceuticals and Wata Chemicals.

ACI returned to profit in the second quarter with an EPS of Tk 0.34, compared to a loss of Tk 3.17 in the same period last year. Beximco Pharmaceuticals posted EPS of Tk 4.10 in Q2, up from Tk 3.21 a year earlier, while Square Pharmaceuticals reported EPS of Tk 8.20, compared to Tk 7.45 in the corresponding period. Renata’s EPS rose to Tk 7.11 from Tk 5.64.

Ibn Sina registered notable growth, with Q2 EPS increasing to Tk 8.20 from Tk 6.75. Beacon Pharmaceuticals, Asiatic Laboratories, and MB Pharma also posted strong year-on-year earnings growth during the quarter.

Marico Bangladesh, which follows a different financial year, reported third-quarter EPS of Tk 47.57 for October–December 2025, up from Tk 44.34 in the same period of the previous year.

On the other hand, EPS declined for Advent Pharma, Far Chemical, JMI Hospital, JMI Syringe and Techno Drugs. Far Chemical incurred a loss of Tk 1.85 per share in the second quarter, compared to an EPS of Tk 0.16 a year earlier. JMI Syringe also slipped into losses, reporting a per-share loss of Tk 1.00 against EPS of Tk 0.98 in the corresponding quarter.

Overall, the majority of companies in the pharmaceuticals and chemicals sector recorded improved earnings in the October–December 2025 quarter, reflecting a generally positive trend in the industry despite some underperformers.